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Down-regulation of DcR2 sensitizes androgen-
dependent prostate cancer LNCaP cells to
TRAIL-induced apoptosis
David Vindrieux1†, Marie Réveiller2†, Jacqueline Chantepie3, Sadok Yakoub4, Catherine Deschildre5, Alain Ruffion6,
Marian Devonec6, Mohamed Benahmed7 and Renée Grataroli8*
Abstract
Background: Dysregulation of many apoptotic related genes and androgens are critical in the development,
progression, and treatment of prostate cancer. The differential sensitivity of tumour cells to TRAIL-induced
apoptosis can be mediated by the modulation of surface TRAIL receptor expression related to androgen
concentration. Our previous results led to the hypothesis that downregulation of TRAIL-decoy receptor DcR2
expression following androgen deprivation would leave hormone sensitive normal prostate cells vulnerable to the
cell death signal generated by TRAIL via its pro-apoptotic receptors. We tested this hypothesis under pathological
conditions by exploring the regulation of TRAIL-induced apoptosis related to their death and decoy receptor
expression, as also to hormonal concentrations in androgen-sensitive human prostate cancer, LNCaP, cells.
Results: In contrast to androgen-insensitive PC3 cells, decoy (DcR2) and death (DR5) receptor protein expression
was correlated with hormone concentrations and TRAIL-induced apoptosis in LNCaP cells. Silencing of androgen-
sensitive DcR2 protein expression by siRNA led to a significant increase in TRAIL-mediated apoptosis related to
androgen concentration in LNCaP cells.
Conclusions: The data support the hypothesis that hormone modulation of DcR2 expression regulates TRAIL-
induced apoptosis in LNCaP cells, giving insight into cell death induction in apoptosis-resistant hormone-sensitive
tumour cells from prostate cancer. TRAIL action and DcR2 expression modulation are potentially of clinical value in
advanced tumour treatment.
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Background
Prostate cancer is the most commonly diagnosed malig-
nancy in the male population and remains the second
leading cause of cancer-related deaths in the developed
world [1]. Inhibition of apoptosis is a critical pathophy-
siological factor that contributes to the onset and pro-
gression of prostate cancer, but the molecular
mechanisms are not entirely understood. Therefore,
insight into the mechanism(s) of the misregulation of
apoptosis could be the basis for developing more
effective therapeutic approaches to destroy apoptosis-
resistant tumour cells, as found in prostate cancer [2].
Treatment with apoptosis-inducing ligands belonging
to the Tumour Necrosis Factor-alpha (TNF-a) family
could be an effective strategy for cancer treatment [3,4].
The best characterized ligands, Fas ligand, TNF-a, and
TNF-a-related apoptosis-inducing ligand (TRAIL, also
known as Apo2L) [5,6], are type II transmembrane pro-
teins that can induce apoptosis in susceptible cells after
binding to type I transmembrane receptors containing
cytoplasmic “death domains”. These interact with the
downstream death domain-containing adapter proteins
FADD or TRADD (for Fas- or TNFR-associated death
domains, respectively), leading to activation of initiator
caspases (e.g. caspase 8) and effector caspases (e.g.
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caspase 3) and apoptotic cell death [7]. Unfortunately,
both TNF-a and Fas ligands have severe systemic cyto-
toxic effects, limiting their use as systemic agents [8].
Unlike TNF-a and FasL, TRAIL has been used effec-
tively in systemic animal trials and has the unique fea-
ture of inducing apoptosis in cancer cells, whilst sparing
normal cells [9,10]. TRAIL may therefore be a promis-
ing candidate for cancer treatment.
Transcripts of TRAIL [5,6] have been detected in
many human tissues (e.g. spleen, thymus, prostate, and
lung). To date, at least 4 type I transmembrane recep-
tors have been identified, including DR4 (TRAIL-R1)
[11], DR5 (TRAIL-R2) [12], DcR1 (TRAIL-R3) [13,14]
and DcR2 (TRAIL-R4) [15,16]. Ligation of TRAIL with
DR4 or DR5 induces trimerization of the receptor,
which activates the apoptotic pathway. In contrast to
DR4 and DR5, DcR1 and DcR2 act as decoy receptors
for TRAIL. DcR1 is a glycosylphosphatidylinositol
(GPI)-linked protein lacking an intracellular domain,
and DcR2 contains a truncated death domain. They can
prevent TRAIL-induced apoptosis, presumably by com-
peting with DR4 and DR5 for binding to TRAIL [12,14].
Because they can bind TRAIL but do not signal for
apoptosis, DcR1 and DcR2 appear to serve as “decoys”
that inhibit apoptosis by sequestering TRAIL from the
death-inducing TRAIL receptors. Moreover, Clancy et
al. [17] reported that inhibition of apoptosis depends on
the formation of ligand-independent complexes between
DR5 and DcR2 in primary human CD8+ T cells.
Finally, osteoprotegerin, a regulator of osteoclastogen-
esis, appears to be a soluble receptor for TRAIL [18].
The idea of targeting specific death receptors to induce
apoptosis in tumours is attractive; thus it is particularly
intriguing to explore how a complex family of death and
decoy receptors modulates TRAIL function. Although
DR4 and DR5 transcripts and TRAIL mRNA are
expressed in many tissues, most normal cells are resis-
tant to apoptosis induction by this ligand [9,10]. There-
fore DcR1 and DcR2 receptors may contribute to
physiological resistance to TRAIL. In contrast, several
tumour cell lines express DR4 and DR5, but little DcR1
and DcR2, suggesting that cancer cells are more sensi-
tive to the TRAIL apoptotic signal. However, some
tumour cells can acquire resistance to TRAIL-induced
apoptosis by up-regulating decoy receptor expression
[19]. Androgens are critically involved in the develop-
ment, progression, and treatment of prostate cancer
[20]. Currently, a major therapy for the treatment of
localized and metastatic prostate cancer is androgen
ablation, which induces extensive apoptosis of andro-
gen-dependent prostate cancer cells, resulting in tumour
regression and improved prognosis [21,22]. Androgen
deprivation by castration induces cell death in hormone-
sensitive rat ventral prostate [23], and caspase-3 and -6
expression and activation are targeted by hormone
action during this process [24]. The involvement of the
death receptor pathway in ventral prostate apoptosis has
been well studied [25-27]. We reported earlier that tes-
tosterone specifically controls DcR2 mRNA and protein
expression in normal adult rat ventral prostate, and con-
cluded that androgen withdrawal by reducing DcR2
expression might leave the cells vulnerable to the cell
death signal generated by TRAIL via its functional
receptors [28].
Although androgen regulation of human TRAIL
receptor expression under pathological conditions has
not been reported, we can hypothesize on the basis of
our previous results that hormonal variations in DcR2
receptor expression levels are involved as inhibitor/indu-
cer in TRAIL-induced apoptosis in prostate cancer cells.
We have investigated the role of the decoy receptor
DcR2 in apoptosis induction by TRAIL in human pros-
tate cancer, using the androgen-sensitive cell line,
LNCaP.
Initially the dose-dependent effects of androgen on
TRAIL system expression showed that the hormone
sensitivity of DcR2 and DR5 protein expression corre-
lates with TRAIL-induced apoptosis. After silencing
DcR2 protein expression with siRNA, we explored the
consequences of the downregulation on TRAIL-induced
apoptosis in LNCaP cells.
Results
Sensitivity of LNCaP Cells to Androgen Concentration
The effect of androgen on TRAIL system expression in
hormone-sensitive prostate cancer cells was examined
using human hormone-sensitive LNCaP cells as a
model. These cells gave a bell-shaped growth curve in
response to increasing doses (1 pM-10 nM) of R1881
(Figure 1A). R1881 concentrations, in the pM range,
induce cell proliferation, with a significant maximum at
0.1 nM (3H incorporation up 4.25-fold, P < 0.002, and
cell number increased 1.9-fold compared with controls,
P < 0.05), whereas doses in nM range impeded cell
growth. DNA content was assessed by flowcytometry
(Figure 1B). Under the best conditions of cell prolifera-
tion (0.1 nM R1881), there was less DNA fragmentation
(P < 0.005) than at other concentrations (Figure 1C);
and globally, compared with control cells, the absence
of a significant increase in the DNA fragmentation per-
centage under all conditions indicated the absence of
apoptosis. Incubation in 10 nM R1881 produced the
highest level of cells in G0-G1 (+28%, P < 0.005) and
the lowest level of cells in G2-M (-50%, P < 0.005) in
comparison with controls (Figure 1D), confirming this
concentration as inhibiting cell growth. In the positive
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control, etoposide, the increase in the DNA fragmenta-
tion percentage (Figure 1C) correlated with a decrease
in the percentage of cells distributed in the 2 corre-
sponding G0-G1 and G2-M stages (Figure 1D), com-
pared with the DMSO control. Except in the positive
control (etoposide), and in accordance with the absence
of apoptosis under all other conditions, cleaved caspase-
3 protein levels were unchanged (data not shown).
Androgen Action on TRAIL System Protein Expression in
LNCaP Cells
To investigate the effect of androgen on TRAIL, DR4,
DR5, DcR1 and DcR2 protein levels, hormone-sensitive
LNCaP cells were cultured in increasing concentrations
of R1881 (1 pM-10 nM). Ligand and receptors protein
levels were measured by Western blot analysis (Figure
2). No significant variations were observed in TRAIL
Figure 1 Androgen control of LNCaP cell proliferation. (A): cells were treated with increasing concentrations of R1881 (1 pM-10 nM) or
ethanol as the control vehicle. Proliferation was measured 4 days later by [3H]-thymidine incorporation with *P < 0.005 versus other
concentrations and by cell number counting with **P < 0.05 versus other concentrations. (B): cell cycle was analysed by flowcytometry after
treatment with R1881 at 1 pM, 0.1 nM, and 10 nM, with its ethanol vehicle as control (Ct) (0.001% was the highest concentration used), and with
300 μM Etoposide (positive control) and its DMSO diluent at 0.03%. A representative cell cycle profile is presented. (C) and (D): Cell cycle
distribution analysis; the values are expressed as the mean ± SD determined from 2 independent experiments, with triplicate cultures per
treatment condition. (C): percentage DNA fragmentation (S-G0), *P < 0.005 versus control and R1881 concentrations, **P < 0.005 versus DMSO.
(D): percentage of cells in G0-G1 and in G2-M with *P < 0.005 and **P < 0.005 versus the other treatment conditions, respectively.
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(present as a doublet), DR4 and DcR1 protein levels
(Figure 2A), whereas DcR2 and DR5 levels were signifi-
cantly increase in the nanomolar range compared to the
control (1.6-fold, P = 0.002, and 5.6-fold, P = 0.003,
respectively, at 1 nM; Figure 2B). All the samples were
run and detected together, but some films were cut and
pasted to remove spots from replicate cell protein
extracts. A correlation was found between androgen
concentration and DcR2 and DR5 protein expression
that corroborated our previous results obtained in nor-
mal prostate (modulation of DcR2 expression [28]) and
testis (modulation of DR4, DR5 and DcR2 expression
[29]), another hormone-sensitive tissue.
There are no reports of androgen responsive elements
in TRAIL receptor promoters. However, the following
experiments show that DcR2 and DR5 expression can
be regulated via the androgen receptor. LNCaP cells
incubated simultaneously with R1881 and the specific
androgen receptor antagonist, bicalutamide (25 μM),
significantly abrogated the increase in DcR2 and DR5
protein expression due to 10 nM R1881 alone (Figure
3A and 3B). Similarly, the DcR2 and DR5 expression
after R1881 incubation was not significantly modified in
prostate cancer cells devoid of androgen receptors, such
as PC3 cells (Figure 3C and 3D).
Androgen Regulates Apoptosis Induction by TRAIL in
LNCaP cells
To investigate TRAIL-mediated cell death related to
androgen concentration, LNCaP cells were cultured for
4 days in 0.1 nM or 10 nM R1881 before being treated
with increasing TRAIL ligand concentrations from 10
ng to 1 μg for 24 and 48 h. Cell death was monitored
by DAPI staining (Figure 4A). Androgen at 0.1 and 10
nM were chosen because they represented the best and
the poorest cell growth conditions, respectively (Figure
1), and because of the variations in DcR2 and DR5 pro-
tein levels (Figure 2). In comparison with androgen-free
conditions (Figure 4B), the percentage of fragmented
nuclei in the presence of 0.1 nM R1881 increased signif-
icantly between 10 and 200 ng TRAIL per milliter
(+28% and + 38% for TRAIL 100 ng and 200 ng, respec-
tively; P < 0.005) to reach a plateau at 300-1000 ng/ml.
TRAIL-induced apoptosis was not assessed at 10 nM
R1881. Results obtained after 48 h treatment were
slightly higher than after 24 h (data not shown). Conse-
quently, the best TRAIL-induced apoptosis conditions
for LNCaP cells were 100 ng of TRAIL over 24 h.
DcR2 Protein Expression is Correlated with TRAIL-
Sensitivity in Prostate Cancer LNCaP Cells
We have reported a correlation between androgen sta-
tus, apoptosis and DcR2 expression in rat prostate [28],
and postulated that DcR2 decoy receptor expression
may be directly related to TRAIL-induced apoptosis
resistance in prostate cancer cells. If so, the downregula-
tion of DcR2 protein expression could reverse resistance
to TRAIL-induced cell death. Since DcR2 and DR5 pro-
tein expression in LNCaP cells is androgen sensitive
(Figure 2), we tested the previous hypothesis by suppres-
sing DcR2 gene expression using siRNA (Figure 5).
Similarly, the role of DR5 was investigated to check its
function and the efficiency of the silencing method.
DcR2 (Figure 5A) and DR5 (Figure 5B) proteins were
knocked down after transfection with the corresponding
siRNAs, which were followed by 48 h incubation in 0.1
nM R1881 (-98% and -92%, respectively, in comparison
with controls (untreated and si0 treated cells), P<
0.005). Protein silencing was less efficient after 96 h
incubation than at 48 h because of the decrease in
siRNA strands and exhaustion of the medium. No sig-
nificant variations were observed in fragmented nuclei
per thousand DAPI-stained cells treated with siDcR2 or
siDR5 alone, or with the different transfection reagents
(scrambled siRNAs/si0 and specific siRNAs, lipofecta-
mine) (Figure 5C), indicating that there were not toxic
materials present.
The 48 h silencing of the DcR2 Protein as described in
Figure 5, followed by treatment with TRAIL as
described in Figure 4, led to a significant increase in
fragmented nuclei (2.13-fold, P < 0.002) in transfected
LNCaP cells in comparison with untransfected control
cells or scrambled siRNA transfected cells (Figure 6A).
This was confirmed by a significant increase in caspase
3 activity in DcR2 siRNA transfected cells and treated
with TRAIL (+26%, P < 0.005) in comparison with
scrambled siRNA transfected or untransfected control
cells with TRAIL, (Figure 6B). Silencing of the DR5 pro-
tein resulted as anticipated in a significant reduction in
TRAIL-induced apoptosis in comparison with untrans-
fected control cells and scrambled siRNA transfected
cells (-54%, P < 0.002), and no significant variation in
caspase 3 activity (Figure 6A and 6B, respectively).
LNCaP cells cultured in 10 nM R1881 showed no
apoptosis without (Figure 1C) or with TRAIL peptide
(Figure 4B), and an increase in DcR2 protein levels (Fig-
ure 2B). Silencing of DcR2 protein at 10 nM R1881
resulted in partial recovery of TRAIL-induced apoptosis
in comparison with untransfected control cells and with
scrambled siRNA transfected cells (3.1-fold and 3.8-fold,
respectively, P < 0.005; Figure 7A), accompanied by a
significant increase in caspase 3 activity in comparison
with si0 transfected cells (+59%, P < 0.05; Figure 7B).
This suggests that DcR2 upregulation rendered LNCaP
cells more resistant to TRAIL-mediated apoptosis,
whereas downregulation of DcR2 protein enhanced
TRAIL-induced apoptosis.
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Figure 2 Androgen control of TRAIL and TRAIL-receptor protein expression in LNCaP cells. Cells were treated for 4 days with increasing
concentrations of R1881 (1 pM-10 nM) or with ethanol vehicle as control (Ct) (0.001% was the highest concentration used). Proteins were
characterized by immunoblot analysis using anti-TRAIL, anti-DR4 and anti-DcR1 antibodies (A), and with anti-DcR2 and anti-DR5 antibodies (B).
Histograms represent corresponding protein levels and are normalized for b-actin expression. The values represent the mean ± SD determined
from triplicate cultures of a representative experiment from 3 independent experiments. For each protein a representative autoradiograph is
shown. *P < 0.005 compared with control.
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Discussion
In the pathological prostate, the physiological regulation
of apoptosis by TRAIL in relation to death and decoy
receptor expression and hormonal concentration is
unknown. Our previous results [28] showed that andro-
gen deprivation associated with an apoptotic process led
to a decrease in DcR2 expression in normal adult rat
hormone sensitive ventral prostate. The downregulation
of DcR2 expression following androgen deprivation was
thought to leave androgen sensitive cells vulnerable to
the cell death signal induced by TRAIL via its pro-apop-
totic receptors.
In the presence of R1881 at 1 pM-10 nM, the growth
curve LNCaP cells was characteristically bell-shaped,
with a peak at 0.1 nM [30,31]. TRAIL, DR4 and DcR1
protein expressions were unaffected under these condi-
tions, whereas DR5 and DcR2 protein expression
increased over a nanomolar range. No androgen respon-
sive elements have been reported in TRAIL-receptor
promoters, but several experimental results suggest the
Figure 3 DcR2 and DR5 protein expression in prostate cancer cells when androgen action had been neutralised. (A) and (B): in LNCaP
cells incubated for 4 days with ethanol vehicle as control (Ct) (0.001% was the highest concentration used) or R1881 at 0.1 nM or 10 nM,
without or with 25 μM antiandrogen bicalutamide. (C) and (D): in PC3 cells, devoid of androgen receptor, incubated for 4 days with ethanol
vehicle as control or increasing concentrations of R1881. All the samples were run and detected together, but some films were cut and pasted
to remove spots from replicate cell protein extracts. Immunoblot results and histograms represent DcR2 and DR5 levels and were normalized to
b-actin expression. The values represent the mean ± SD determined from triplicate cultures of a representative experiment from 2 independent
experiments. For each protein a representative autoradiograph is shown. *P < 0.05 versus the other treatment conditions.
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Figure 4 Androgen regulation of TRAIL-induced apoptosis in LNCaP cells. After 4 days of culture with ethanol vehicle (Ct: control), or
R1881, LNCaP cells were treated with increasing TRAIL concentrations for 24 h. (A): fragmented nuclei were investigated after DAPI staining by
fluorescence microscopy. (B): the number of fragmented nuclei was determined in LNCaP treated with increasing TRAIL concentrations for 24 h.
The values represent the mean ± SD of fragmented nuclei per 1,000 cells after analysis of 5,000 randomly selected cells per culture and
determined from 5 replicate cultures of a representative experiment from 3 independent experiments. *P < 0.005 versus TRAIL treated cells in
androgen free and 10 nM R1881 conditions.
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genomic regulation of DR5 and DcR2 expression by
androgens occurs in the same way as their inhibition by
the anti-androgen, bicalutamid, and receptor expression
remains unmodified in PC3 cells incubated with andro-
gen. However, its regulation by an (as yet unidentified)
androgen-dependent transcription factor is possible, and
the increased DcR2 protein level in LNCaP cells may be
due to its regulation by an (also as yet unidentified)
androgen-dependent translational factor.
TRAIL-induced apoptosis of LNCaP cells is maximal
at 0.1 nM R1881. Increases in DR5 and DcR2 receptor
expression at R1881 concentrations of up to 0.1 nM
may be related to the absence of TRAIL induced apop-
tosis in situations of poor cell proliferation. Silencing of
hormone sensitive receptors with siRNA shows that, at
0.1 nM R1881, and when DcR2 protein expression is
silenced by the corresponding siRNA, TRAIL-induced
apoptosis is increased by a factor of 2 in comparison
with the controls. In contrast and as expected, apoptosis
could be reduced to half when DR5 is silenced, which
may be due to pro-apoptotic receptor DR4 expression
not being downregulated. DcR2 is therefore a regulator
of TRAIL induced apoptosis in the best hormonal con-
centration for cell growth. Moreover, preliminary results
show that the silencing of the DcR2 receptor results in a
partial restoration of TRAIL induced apoptosis in other-
wise resistant LNCaP cells cultured in 10 nM R1881. A
partial restoration of TRAIL mediated apoptosis in 10
nM androgen may be due to poor cell growth involving
an intracellular signalling and trafficking that is much
slower than in the favourable growth conditions (0.1
nM) in vitro.
Rokhlin et al. [32] showed that the expression level of
the DR4 and DR5 receptors in LNCaP incubated with
fetal calf serum or 100 nM dihydrotestosterone was
clearly superior to the control conditions without andro-
gen, whereas the decoy receptor expression level was
not given. Although these authors [33], like others [34],
Figure 5 SiRNAs specific for DcR2 and DR5 suppress gene expression in LNCaP cells. Gene-specific siRNAs and scrambled siRNAs controls
(si0) (0.5 μg) were added to the media using lipophilic transfection-enhancing reagent (lipofectamine/lipo) for 4 h, and then the cells were
cultured in media containing 0.1 nM R1881. Cells were harvested after 48 or 96 h for immunoblot analyses with DcR2 (A) and DR5 (B) specific
antibodies. The blots were reprobed with antibody against ß-actin to confirm equal protein loading (15 μg). All the samples were run and
detected together but 96 h films were cut and pasted to remove spots from replicate cell protein extracts. Representative autoradiograph results
are shown and histograms represent DcR2 (right scale: 48 h incubation; left scale: 96 h incubation) and DR5 protein levels and were normalized
for ß-actin expression. (C): the number of fragmented nuclei per 1,000 cells was determined in all transfection treatment conditions (scrambled
and specific siRNAs and lipofectamine) with DAPI method. The values represent the mean ± SD determined from triplicate cultures of a
representative experiment from 3 independent experiments. *P < 0.005 versus the other treatment conditions.
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Figure 6 Inhibition of DcR2 and DR5 protein expression by siRNA sensitizes LNCaP cells to TRAIL-induced apoptosis in medium
containing 0.1 nM R1881. LNCaP cells, untransfected (Ct: control) or transfected with scrambled siRNA (si0) or siDcR2 or siDR5 (0.5 μg) for 48 h
were treated with TRAIL (100 ng/ml) for 24 h (A). White arrows show fragmented nuclei detected by the DAPI method. Histograms represent the
number of fragmented nuclei per 1,000 cells from 5,000 randomly selected cells per culture. The values represent the mean ± SD determined
from triplicate cultures of a representative experiment from 3 independent experiments. a, P < 0.005, *P < 0.005 and **P < 0.005 versus the
other treatment conditions. TRAIL-induced apoptosis, under previous conditions, was controlled by caspase-3 activity assay (B). Histogram values
represent the mean ± SD determined from triplicate cultures of a representative experiment from 2 independent experiments performed at 0.1
nM R1881, *P < 0.005 versus the other treatment conditions.
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found resistance of LNCaP cells to TRAIL-induced
apoptosis, interestingly they also showed that FADD and
caspase 8 recruitment for TRAIL-DISC formation and
cell death induced by the TRAIL ligand were androgen-
related in LNCaP cells [32,35]. These results along with
ours support the hypothesis that LNCaP sensitivity to
the TRAIL ligand is androgen-regulated, and related to
the expression of its receptors (decoy and pro-apoptotic)
and DISC formation [32,35]. In contrast, no significant
variations for DR4 expression were observed under our
conditions with R1881 present under 10 nM, which may
be due to differences in experimental conditions (andro-
gen concentration, pH, media composition, temperature,
timing of treatment, presence of PI3K/Akt pathway inhi-
bitor, etc.). The relative contribution of each death
receptor to apoptosis induction in cells expressing both
receptors remains unknown [4]. In vitro, comparison of
TRAIL-death receptors cell surface expression and
TRAIL sensitivity of cancer cell lines did not show any
consistent pattern, suggesting that TRAIL sensitivity
may be dependent on a permissive environment for pre-
ferential signalling via TRAIL-DR4 or DR5 receptors
expression controlled by other intracellular mechanisms
in resistant cells [36,37]. Our data indicates that andro-
gens play a role in apoptosis sensitivity in LNCaP cells,
and their resistance to TRAIL-induced apoptosis is
more closely linked to the upregulation of the decoy
receptor DcR2 expression than to downregulation of
pro-apoptotic receptors.
Considering the context of the pathological and hor-
mone-sensitive prostate, these results, like others [38],
show that the resistance of such tissues to apoptosis is
Figure 7 Inhibition of DcR2 protein expression by siRNA sensitizes LNCaP cells to TRAIL-induced apoptosis, in medium containing 10
nM R1881. LNCaP cells, untransfected (Ct: control) or transfected with scrambled siRNA (si0) or siDcR2 (0.5 μg) for 48 h were treated with TRAIL
(100 ng/ml) for 24 h. (A) Histograms represent the number of fragmented nuclei per 1,000 cells from 5,000 randomly selected cells per culture.
The values represent the mean ± SD determined from triplicate cultures of a representative experiment from 3 independent experiments. *P <
0.005 versus the other treatment conditions. (B) TRAIL-induced apoptosis, under previous conditions, was controlled by caspase-3 activity assay.
Histogram values represent the mean ± SD determined from triplicate cultures of a representative experiment from 2 independent experiments
performed at 10 nM R1881, *P < 0.05 with the Fisher post-test versus the other treatment conditions, except the control with TRAIL.
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probably more closely linked to increased expression of
apoptosis inhibitors than decreased expression of pro-
apoptotic proteins. This hypothesis is strengthened by
other data showing that the silencing of Bcl2, FLIP or
IAPs (XIAP and survivine) by siRNAs sensitizes resistant
melanoma cells to TRAIL-induced apoptosis [39]. In the
same way, Sung et al. [40] reported that celastrol, a tri-
terpene, enhanced TRAIL-induced apoptosis through
the downregulation of cell survival proteins and upregu-
lation of death receptors. Hesry et al. [41] showed that
sensitivity to the TRAIL ligand is related to tumour pro-
gression (in LNCaP, DU 145, PC3 cells) and that
TRAIL-induced cell death is only linked to the DR5
receptor, moreover they found DcR1 receptor expres-
sion to be undetectable, whereas DcR2 was significantly
more abundant in tumour cells than non-neoplastic
cells, and may thus contribute to the partial resistance
to TRAIL found in some prostate tumour cells (e.g.
LNCaP and DU 145). Interestingly, another study [42]
reported that the combined treatment of prostate cancer
cells (LNCaP and PC3) with TRAIL and chemothera-
peutic agents overcame their resistance by triggering
caspase activation; in the same way Sanlioglu et al. [43]
indicated that DcR2 siRNA and adenovirus delivery of
TRAIL dramatically affected the tumorigenic potential
of prostate cancer LNCaP and DU 145 cells.
If androgen withdrawal in prostate cancer treatment
decreases anti-apoptotic gene expression as DcR2 in
androgen-dependent cells, this could induce apoptosis,
resulting in prostate tumour reduction. Over the middle
term and following androgen withdrawal [44], it is con-
ceivable that androgen-independent cancer cells might
arise as a subpopulation that has acquired the capacity
to upregulate the expression of decoy receptors and per-
haps other anti-apoptotic proteins, such as XIAP [45];
in this way they might escape anti-tumour surveillance
by immune cells. Under these conditions, upregulation
of anti-apoptotic proteins would be independent of
androgen deprivation. Furthermore, the identification of
drugs or experimental methods (downregulation by siR-
NAs) that decrease TRAIL decoy receptor expression
for a long time after androgen ablation may prove to be
useful therapeutically on their own, or in combination
with other approaches (molecular/protein targets, cyto-
toxic agents, etc.) to induce apoptosis as treatment for
prostate cancer and/or for otherwise resistant cancer
cells.
Conclusions
The differential sensitivity of tumour cells to TRAIL-
induced apoptosis may be mediated by the modulation
of surface TRAIL receptor expression that could be
related to the androgen concentration in prostate.
Decoy (DcR2) and death (DR5) receptor protein
expression is correlated with hormone concentrations
and TRAIL-induced apoptosis in LNCaP cells. Silencing
of androgen-sensitive DcR2 protein expression by
siRNA leads to a significant increase in TRAIL-mediated
apoptosis related to androgen concentration in LNCaP
cells. The data support the view that hormone modula-
tion of DcR2 expression is involved in regulating
TRAIL-induced apoptosis in the androgen-sensitive
prostate carcinoma cell line, LNCaP, and provides preli-
minary insight into cell death induction in apoptosis
resistant hormone-sensitive prostate cancer cells. TRAIL
action and DcR2 expression modulation are potential of
clinical value for advanced tumour treatment when
androgen-deprivation therapy fails, leading to recurrent
tumour growth in a hormone-refractory manner.
Furthermore, the identification of drugs or experimen-
tal methods that enhance TRAIL-induced apoptosis
through the downregulation of TRAIL decoy receptor or
cell survival proteins expression may prove themselves
to be therapeutically useful, or in combination with
other therapeutic approaches to induce apoptosis as
treatment for prostate cancer or for otherwise resistant
cancer cells.
Materials and methods
Cell Culture
Human prostatic carcinoma cell lines, LNCaP and PC3,
were obtained from the American Type Culture Collec-
tion (ATCC, Bethesda, MD). Cells were maintained in
RPMI 1640 medium (Invitrogen, Cergy-Pontoise,
France), supplemented with 7.5% fetal calf serum (FCS;
Invitrogen), 2 mM L-Glutamine (Sigma, Isle d’Abeau,
France), 20 μg/ml streptomycin, 20 U/ml penicillin
(Invitrogen), and 50 U/ml Nystatin (Sigma). LNCaP and
PC3 cells were used between passages 50-60 and 18-24,
respectively. 17b-hydroxy-17-methyl-estra-4,9,11-trien-3-
olone (R1881/testosterone analogue) was purchased
from New England Nuclear (Boston, MA) and dissolved
in ethanol. Bicalutamide (Casodex, [(2RS)-4’-cyano-3-(4-
fluorophenylsulphonyl)-2-hydroxy-2-methyl-3’-trifluoro-
methyl propioanilide] was a gift from AstraZeneca
(Alderly House, Cheshire, England); it was dissolved in
0.2% methanol.
Cell numeration, proliferation assay and treatment
LNCaP cells (5 × 104) were plated in triplicate per well
in 24-well plates (Corning Incorporated, Corning, NY)
in steroid-depleted media containing 2.5% charcoal-
stripped FCS (HyClone, Logan, UT) for numeration.
Cells of each well were counted in duplicate with a
Coulter Z1 counter (Beckman Coulter, CA). For [3H]-
thymidine incorporation, cells were plated in 12-well
plates at 12 × 104 cells/well and incubated with 0.5 μCi/
ml [3H]-thymidine (Du Pont-New England Nuclear, Les
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Ulis, France) in medium for 4 h before harvesting. Cells
were washed twice with ice-cold PBS and DNA precipi-
tated with 5% trichloracetic acid. The DNA precipitate
was dissolved in 0.4 ml of 0.25 M NaOH and incorpo-
rated [3H]-thymidine was determined by liquid scintilla-
tion counting. Sampling at each time-point was in
triplicate. For Western-blotting analysis, LNCaP cells
were seeded in 10 cm disks (22 × 105 cells), with 3 disks
per condition. Cells were allowed to attach for 24 h and
treated with various concentrations of R1881 on day 0.
All the cells, including the control cells, were cultured
in the presence of the same ethanol concentration
(0.001% being the highest concentration used).
Flowcytometric Analysis
Flowcytometry was used to assess the sub-G1 DNA
population of cells undergoing apoptosis. LNCaP cells
were seeded at 8 × 105 cells in 6-cm dishes. After 4
days of culture with or without R1881, cells were col-
lected by trypsinization and fixed in 1% paraformalde-
hyde for 30 min at 4°C, then in 70% ethanol/30% PBS
(phosphate buffer saline) for 2 h at -20°C. Fixed cells
were washed with PBS, treated with 30 μg/ml Rnase A
in PBS for 60 minutes at 37°C, and propidium iodide in
PBS (10 μg/ml) was added. For positive controls, LNCaP
were incubated with etoposide (Sigma) diluted with
0.03% DMSO (dimethyl sulfoxide; Sigma). Cell cycle
profiles and distributions were determined using a BD
Facscan flowcytometer (Becton Dickinson Biosciences,
San Jose, CA). Cell cycle distribution was analyzed using
Modfit LT software (Verity Software House, Topsham,
ME).
Western-blot analysis
Cell protein extracts were prepared by direct addition of
5 volumes of cold lysis buffer, as previously described
[40]. Protein concentration was determined using the
Bicinchoninic acid assay reagent (Sigma, Isle d’Abeau,
France), with bovine serum albumin as standard. Protein
samples (15 μg/well) were resolved by 12% SDS-polya-
crylamide gel electrophoresis and electroblotted as
described earlier [46]. Nitrocellulose blots were treated
and incubated with the following primary antibodies
(Santa Cruz Biotechnology, Santa Cruz CA): rabbit poly-
clonal antibodies raised against human TRAIL or DR4
(1:1,000), goat polyclonal antibodies raised against
human DcR1 or DcR2 (1:1,000) and secondary antibo-
dies, horseradish peroxidase (HRP) conjugated goat anti-
rabbit IgG (1:2000) or donkey anti-goat IgG (1:5,000) as
previously reported [28]. The primary antibody anti-
human DR5, obtained from AnaSpec, Incorporated (San
Jose, CA), was used at a dilution of 1:1000. Protein load-
ing was checked by reprobing the blot with a rabbit IgG
anti-b-actin antibody (1/500) (Sigma). Bound antibodies
were detected using the chemiluminescence Western
blotting detection kit (Covalab). The Biomax MR films
(Eastman Kodak Company, Rochester, NY) were
scanned on a Gel doc 2000 apparatus (Biorad, Marnes-
la-Coquette, France), and quantified with Quantity one
Software Biorad.
Apoptosis assessment with 4’, 6’-diamidino-2
phenylindole staining (DAPI)
LNCaP cells undergoing apoptosis were followed by
chromatin condensation, nuclear shrinkage, and forma-
tion of apoptotic bodies, as visualized after DAPI stain-
ing [47]. Following various specific treatments, the
medium was removed and cells fixed in ethanol/acetic
acid (3:1, vol/vol) at room temperature for 10 min. Cells
were washed with 0.9% NaCl and stained with 0.4 μg/ml
DAPI in 0.9% NaCl at room temperature for 30 min
and viewed by fluorescence microscopy.
si RNA
siRNAs (sense and antisense strands) were purchased
from Ambion, Inc. (Austin, TX). The sense strand
sequences were the following: DR5, 5’-GGACUAUAG-
CACUCACUGGtt-3’; DcR2, 5’-GGGUGUGGAUUA-
CACCAUUtt-3’; siRNA control was a non-specific
random scrambled sequence. In vitro transfections used
lipofectamine reagent (Invitrogen, Cergy-Pontoise,
France). Cells were cultured in 12-well plates, 1 ml/well
of 2.5% charcoal-stripped FCS medium. They were
allowed to attach for 24 h, the culture medium was then
removed and replaced with serum-free RPMI (200 μl).
Cells were treated with gene-specific siRNAs and con-
trol siRNAs (0.5 μg), plus reagent (2 μl), lipofectamine
reagent (1 μl) and 50 μl of RPMI for 4 h at 37°C with
5% CO2 in air. Thereafter, 750 μl of 2.5% charcoal-
stripped FCS-containing medium were added. Cells
were collected or treated 48 h later with TRAIL peptide
(PeproTech, Levallois Perret, France). The silencing of
targeted proteins was estimated by Western-blot analysis
with corresponding antibodies.
Colorimetric caspase-3 activity assay
The enzymatic activity of caspase-3 was assayed with a
Caspase-3 Colorimetric Assay Kit (Alexis Biochemicals,
Switzerland). To measure the activity of caspase-3, cell
lysates were prepared after their respective treatments.
After incubating 200 μg protein of cell lysate per sample
in 100 μl of reaction buffer containing DEVD-pNA sub-
strate (200 μM final concentration) at 37°C for 2 h in
the dark, absorption was measured at 405 nm.
Statistical analysis
Statistical analysis were carried out by ANOVA and
post-hoc Bonferroni/Dunn tests, except in Figure 3,
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where significant differences were obtained with the
Student-Newman-Keuls post-test (StatView Software;
SAS Institute Inc., Cary, NC). Differences were taken as
statistically significant at P < 0.05. A representative
experiment of each series is presented.
Data are expressed as the mean ± SD. Unless other-
wise mentioned in the figure legends, the different ana-
lyses were performed 3 times with triplicate cultures,
and investigated at least 3 times on cells at different
passages. TRAIL-induced apoptosis experiments
included 5 samples per treatment condition.
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